Targets › RXFP1
2 programs from 2 companies in 2 trials: 2 Phase 2; Cardiovascular, Genitourinary; next expected readout Dec 2026.
Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP. (UniProt, Q9HBX9)
Open in Phaseline: the race on RXFP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Relaxin RLN2-encoded endogenous peptide hormone that binds to G protein-coupled receptor RXFP1 | RLN2, RXFP1 | Phase 2 | Cardiovascular Diseases | Dec 2026 |
| River 2 Renal | R2R01 Relaxin receptor agonist | RXFP1 | Phase 2 | Acute Kidney Injury | Apr 2027 |
Cardiovascular Diseases (1) Acute Kidney Injury (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.